311.68

OZIP Plus 3/25mg (Olanzapine 3mg + Fluoxetine 25mg) – 10 Capsules | Glitz Pharma

logo
In stock

Description

OZIP Plus 3/25mg contains Olanzapine 3mg and Fluoxetine 25mg, a combination prescription medicine supplied in capsule form. According to the attached product packaging, each capsule contains Olanzapine 3mg + Fluoxetine 25mg, and the pack contains 10 capsules. The product is manufactured by Glitz Pharma and carries an Rx symbol.

For customers searching for OZIP Plus 3/25mg capsules, Olanzapine 3mg Fluoxetine 25mg capsules, OZIP Plus 10 capsules, or Olanzapine Fluoxetine combination medicine, this product provides a clearly labeled combination strength in a convenient capsule formulation.

Olanzapine and fluoxetine are prescription medicines that affect different neurotransmitter systems and may be prescribed together for specific psychiatric conditions. Use OZIP Plus only under the supervision of a qualified healthcare professional. Do not start, stop, or change the dosage without medical advice.

Purpose

OZIP Plus 3/25mg provides a fixed combination of Olanzapine 3mg and Fluoxetine 25mg for patients for whom this combination has been prescribed by a qualified healthcare professional.

Key Features

  • Brand: OZIP Plus
  • Active ingredients: Olanzapine + Fluoxetine
  • Olanzapine strength: 3mg
  • Fluoxetine strength: 25mg
  • Dosage form: Capsule
  • Pack size: 10 capsules
  • Prescription medicine: Rx
  • Manufacturer: Glitz Pharma

Benefits

  • Provides a fixed-dose combination of olanzapine and fluoxetine.
  • Convenient capsule dosage form.
  • Clearly labeled 3mg/25mg combination strength.
  • Supplied in a convenient 10-capsule pack.

Pros

  • Combination formulation
  • Clearly labeled 3mg olanzapine + 25mg fluoxetine strength
  • Convenient capsule format
  • 10-capsule pack

Cons

  • Prescription medicine requiring professional supervision
  • May cause side effects in some individuals
  • May not be appropriate for everyone
  • Potential interactions with other medicines require professional review

Active Ingredients

Olanzapine 3mg + Fluoxetine 25mg

Dosage Form

Capsule

Pack Size

10 Capsules

Drug Class

Combination of an atypical antipsychotic and an SSRI antidepressant

Manufacturer

Glitz Pharma

Storage Instructions

Store according to the instructions provided on the product packaging. Keep out of reach of children and protect from excessive heat, moisture, and direct sunlight.

Precautions

Use OZIP Plus 3/25mg only as directed by a qualified healthcare professional. Inform your doctor or pharmacist about all medicines and supplements you are taking and any relevant medical conditions. Do not change the prescribed dose or discontinue treatment without professional medical advice.

Product Specifications

SpecificationDetails
Product NameOZIP Plus 3/25mg
Active IngredientsOlanzapine + Fluoxetine
Olanzapine Strength3mg
Fluoxetine Strength25mg
FormCapsule
Pack Size10 Capsules
Drug ClassAtypical Antipsychotic + SSRI
Prescription StatusRx
ManufacturerGlitz Pharma
Size

,

Brand

GLITZ PHARMA

Introducing Glitz Pharma – your trusted partner in advancing health through innovation, quality, and care.At Glitz Pharma, we specialize in producing high-quality pharmaceutical products that combine scientific excellence with a commitment to global health standards. We believe in modernizing healthcare while preserving the integrity and values that form the foundation of effective medicine. With a strong foundation in GMP-certified manufacturing and a growing global footprint, Glitz Pharma continues to deliver consistent value in the ever-evolving world of healthcare.As a leading pharmaceutical manufacturer and distributor, we are dedicated to offering reliable, accessible, and safe medical solutions through our expansive Pharma Services Distribution—reaching patients and healthcare providers across multiple regions.
logo

Reviews

There are no reviews yet.

Be the first to review “OZIP Plus 3/25mg (Olanzapine 3mg + Fluoxetine 25mg) – 10 Capsules | Glitz Pharma”

Your email address will not be published. Required fields are marked *